Evidence map›Paper›PMID 36615499›Full record

ArticleMolecules (Basel, Switzerland)2022

Smart Pellets for Controlled Delivery of 5-Fluorouracil.

Mohammad F Bayan, Abdolelah Jaradat, Mohammad H Alyami, Abdallah Y Naser

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohammad F BayanFaculty of Pharmacy, Philadelphia University, P.O. Box 1, Amman 19392, Jordan.ORCID 0000-0002-1736-1799
Abdolelah JaradatFaculty of Pharmacy, Isra University, P.O. Box 33, Amman 11622, Jordan.ORCID 0000-0003-4775-6238
Mohammad H AlyamiDepartment of Pharmaceutics, College of Pharmacy, Najran University, Najran 66462, Saudi Arabia.ORCID 0000-0003-2731-1071
Abdallah Y NaserFaculty of Pharmacy, Isra University, P.O. Box 33, Amman 11622, Jordan.ORCID 0000-0001-8440-7446

Funding

Philadelphia University 511/34/100 PU
6 · The paper itself

Abstract

This work aimed to develop a new one-pot and readily scaled-up formulation capable of retaining 5-fluorouracil and prolonging its release to obtain a site-specific medication delivery for the potential treatment of colorectal cancer. Six polymer-based formulations were successfully produced using a thermal bulk polymerization method and loaded with 5-fluorouracil, which is a chemotherapeutic agent used in the treatment of colorectal carcinoma. The pellets produced were characterized by measuring the glass transition temperature, tensile strength, Young's modulus, and tensile elongation at break. Studies on in vitro swelling and release were carried out in phosphate-buffered saline to evaluate the behaviour of the developed system. The Young's modulus, glass transition temperature, and tensile strength all increased significantly as the crosslinker concentration increased, but the fracture strain value reduced significantly. The in vitro swelling profile of the produced formulations was significantly reduced by increasing crosslinking density. Less than 27% cumulative drug release was achieved for all formulations after 5 h of starting the release study. The highest cumulative drug release reached after 24 h was 69%. The developed drug delivery system demonstrated the ability to delay the release of 5-fluorouracil in upper gastrointestinal tract-mimicking conditions, while permitting its release in a controlled way afterward, which makes it promising for the potential delivery of 5-fluorouracil to the colon.

Indexed as

Drug Delivery SystemsFluorouracilColonDrug ImplantsPolymersDrug ImplantsFluorouracilPolymers5-fluorouracilcolorectal carcinomasmart polymersspecific drug deliverysustainable materials

Identifiers

PMID36615499
PMCPMC9822034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.